Policing IPR boundaries
The patent battle this time is of a different kind. Small biotech vs. big pharma; Integra Lifesciences vs. Merck in the US Supreme Court. After hearing a lot on classic innovator vs. generic patent suits, this new turn in patent litigation is thought provoking.

Approval of generic drugs
The Hatch-Waxman Act aims at promoting generics without putting them through the tough and long approval process involving clinical trials etc so that the burden on patients can be reduced, say Parikshit Bansal and Anand Sharma